Search clinical trials for: Nilotinib with Imatinib

Total 21201 results

Tianjin Medical University Cancer Institute and...

Recruiting

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT)

Non Small Cell Lung Cancer

China
Fox Chase Cancer Center
Novartis

Terminated

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Metastatic Disease | GIST

United States
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

Non-small-cell Lung Cancer

China
Seoul St. Mary's Hospital
Novartis

Unknown

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib (RE-NICE)

Chronic Myeloid Leukemia

Korea, Republic of
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Li Peng
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (Icotinib)

Neurofibromatosis Type 2 | Vestibular Schwannoma

China
Anhui Medical University

Unknown

Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy

NSCLC

China
Novartis Pharmaceuticals

Completed

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Gastrointestinal Stromal Tumors

United States, France, Italy
Betta Pharmaceuticals Co., Ltd.

Recruiting

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Non-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive Mutation

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

NSCLC

China
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

Chronic Myeloid Leukemia

China
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM)

Chronyc Myeloid Leukemia

Netherlands, Italy
Novartis Pharmaceuticals

Terminated

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (MACS0375)

Gastrointestinal Stromal Tumors

China, Argentina, Russian Federation, Thailand, Korea, Republic of, Brazil, Canada, Venezuela, Mexico
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease

Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Terminated

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENEST)

Myelogenous Leukemia

United States, Germany, Belgium, Italy, Spain, Korea, Republic of, Brazil, Japan, Australia, Czech Republic
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study (LAL1408)

Stem Cell Transplantation | Treatment

Italy
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Betta Pharmaceuticals Co., Ltd.
Tigermed Consulting Co., Ltd

Completed

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Psoriasis

China
University Hospital, Lille
Novartis

Completed

Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (DoubleITK)

Graft Versus Host Disease

France, Belgium
Sichuan Cancer Hospital and Research Institute

Unknown

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Lung Cancer Stage IV
Novartis Pharmaceuticals

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

Chronic Myelogenous Leukemia

China, Argentina, Russian Federation, Germany, Guatemala, Panama, Colombia, Mexico, Brazil, India, Poland, Venezuela
Hospital Universitario Dr. Jose E. Gonzalez
Novartis Pharmaceuticals

Completed

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

Leukemia, Myeloid, Chronic, BCR-ABL Positive

Mexico
Zhejiang Cancer Hospital

Unknown

Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Completed

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) (ENESTnd)

Myelogenous Leukemia, Chronic

South Africa, Italy, Belgium, Japan, Taiwan, Turkey, Canada, Germany, Spain, Egypt, United States, Singapore, Austria, France, Netherlands, Sweden, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Russian Federation, Brazil, Hungar... and more
Wu Nan

Not yet recruiting

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

Non-Small Cell Lung Cancer
Novartis Pharmaceuticals

Completed

A Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)

Gastrointestinal Stromal Tumor (GIST)

China, South Africa, United States, France, Italy, United Kingdom, Germany, Taiwan, Turkey, Canada, Egypt, Singapore, Argentina, Austria, Poland, Russian Federation, Spain, Sweden, Thailand, Korea, Republic of, Bulgaria, Denmark, Japan and more
University of Pisa

Recruiting

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study (TIKlet)

Chronic Myeloid Leukemia

Italy
Prof. Dr. Nikolas von Bubnoff
Novartis

Terminated

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years (DECLINE)

Chronic Myeloid Leukemia

Germany
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Leukemia

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer (CHALLENGE)

Plasma EGFR Mutation-positive Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE)

NSCLC

China
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
Assiut University

Unknown

Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Sun Yat-sen University

Terminated

Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Metastatic Breast Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Non-small Cell Lung Cancer | Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
Betta Pharmaceuticals Co., Ltd.

Unknown

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Tianjin Medical University Cancer Institute and...

Unknown

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

Non-small Cell Lung Cancer

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects

Healthy

China
Bristol-Myers Squibb

Completed

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Leukemia, Myeloid, Chronic-Phase (CML-CP)

3

Subscribe